Skip to main content
NCBI home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 2004 Jun;12(2):99–108. doi: 10.1080/10647440400003972

Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: 2. Factors that may have influenced the marked changes in sales volumes during the 1990s.

Per-Anders Mårdh 1, Jolanta Wågström 1, Maria Landgren 1, Jan Holmén 1
PMCID: PMC1784592  PMID: 15739824

Abstract

BACKGROUND: The epidemiology of vulvovaginal candidiasis (VVC) and such recurrent infections (RVVC) has been difficult to study as the majority of episodes of these conditions are self-treated by the women affected. In Sweden, all pharmacies are owned by the state and all prescriptions and over-the-counter (OTC) products, such as antifungals, are registered in a database, which offers unique possibilities to study the epidemiology of VVC/RVVC. OBJECTIVES: To analyze all prescriptions and OTC products purchased for therapy of VVC/RVVC and to establish reasons for any observed variation in the sales figures. METHODS: Sales figures in the Swedish county of Skåne of antifungal drugs for therapy of VVC/RVVC were analyzed by the aid of the 'ACS' database of the National Corporation of Swedish Pharmacies for the years 1990--1999. The size of the female population in the county is approximately half a million. RESULTS: The study showed that 93% of all antifungal drugs for VVC/RVVC were sold as OTC products. An increase in sales of the drugs occurred until mid- 1993/94, followed by a decrease until end of the study period in 1999. Demographic factors (e.g. the number of female inhabitants in the county, pharmacies and health-care units), the pregnancy rate and pharmacy-dependent factors (such as the introduction of shelves for self-selection of antifungal products) did not explain the observed variations in sales. Distinct short-term variations in the number of prescriptions of fluconazole and itraconazole could be explained by drugs company sales campaigns and logistics factors in drug distribution. The sales volumes in the 33 municipalities in the county correlated with the density of the population, which was not the case for the total number of prescriptions made in the county during the 1990s. The variation in antifungal drug sales was similar to that of hormonal intrauterine devices, but this was not the case for oral contraceptives. The total Swedish usage of antibiotics showed a similar variation to that of the antifungal drugs analyzed. CONCLUSION: The study stresses the limited impact on the treatment of VVC/RVVC by the medical community. Behavior-related factors in the female population are the most likely explanation for the marked variations found in the usage of drugs for the two conditions.

Full Text

The Full Text of this article is available as a PDF (107.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown D., Jr, Binder G. L., Gardner H. L., Wells J. Comparison of econazole and clotrimazole in the treatment of vulvovaginal candidiasis. Obstet Gynecol. 1980 Jul;56(1):121–123. [PubMed] [Google Scholar]
  2. Calderón-Márquez J. J. Itraconazole in the treatment of vaginal candidosis and the effect of treatment of the sexual partner. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S143–S145. doi: 10.1093/clinids/9.supplement_1.s143. [DOI] [PubMed] [Google Scholar]
  3. Cederlund H., Mårdh P. A. Antibacterial activities of non-antibiotic drugs. J Antimicrob Chemother. 1993 Sep;32(3):355–365. doi: 10.1093/jac/32.3.355. [DOI] [PubMed] [Google Scholar]
  4. Eckert L. O., Hawes S. E., Stevens C. E., Koutsky L. A., Eschenbach D. A., Holmes K. K. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol. 1998 Nov;92(5):757–765. doi: 10.1016/s0029-7844(98)00264-6. [DOI] [PubMed] [Google Scholar]
  5. Geiger A. M., Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology. 1996 Mar;7(2):182–187. doi: 10.1097/00001648-199603000-00013. [DOI] [PubMed] [Google Scholar]
  6. Irving G., Miller D., Robinson A., Reynolds S., Copas A. J. Psychological factors associated with recurrent vaginal candidiasis: a preliminary study. Sex Transm Infect. 1998 Oct;74(5):334–338. doi: 10.1136/sti.74.5.334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mårdh P. A., Tchoudomirova K., Elshibly S., Hellberg D. Symptoms and signs in single and mixed genital infections. Int J Gynaecol Obstet. 1998 Nov;63(2):145–152. doi: 10.1016/s0020-7292(98)00140-4. [DOI] [PubMed] [Google Scholar]
  8. Mårdh Per-Anders, Novikova Natalia, Stukalova Elena. Colonisation of extragenital sites by Candida in women with recurrent vulvovaginal candidosis. BJOG. 2003 Oct;110(10):934–937. [PubMed] [Google Scholar]
  9. Mårdh Per-Anders, Rodrigues Acacio G., Genç Mehmet, Novikova Natalia, Martinez-de-Oliveira J., Guaschino Secondo. Facts and myths on recurrent vulvovaginal candidosis--a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS. 2002 Aug;13(8):522–539. doi: 10.1258/095646202760159639. [DOI] [PubMed] [Google Scholar]
  10. Pina-Vaz C., Sansonetty F., Rodrigues A. G., Martinez-De-Oliveira J., Fonseca A. F., Mårdh P. A. Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J Med Microbiol. 2000 Sep;49(9):831–840. doi: 10.1099/0022-1317-49-9-831. [DOI] [PubMed] [Google Scholar]
  11. Rodrigues A. G., Mârdh P. A., Pina-Vaz C., Martinez-de-Oliveira J., da Fonseca A. F. Is the lack of concurrence of bacterial vaginosis and vaginal candidosis explained by the presence of bacterial amines? Am J Obstet Gynecol. 1999 Aug;181(2):367–370. doi: 10.1016/s0002-9378(99)70563-6. [DOI] [PubMed] [Google Scholar]
  12. Rodrigues A., Vaz C. P., Mårdh P. A., da Fonseca A. F., de Oliveira J. M. In vitro effect of fibrinogen on Candida albicans germ tube formation. APMIS. 1999 Nov;107(11):1020–1022. [PubMed] [Google Scholar]
  13. Schaaf V. M., Perez-Stable E. J., Borchardt K. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Intern Med. 1990 Sep;150(9):1929–1933. [PubMed] [Google Scholar]
  14. Sihvo S., Ahonen R., Mikander H., Hemminki E. Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization patterns. Fam Pract. 2000 Apr;17(2):145–149. doi: 10.1093/fampra/17.2.145. [DOI] [PubMed] [Google Scholar]
  15. Sobel J. D., Faro S., Force R. W., Foxman B., Ledger W. J., Nyirjesy P. R., Reed B. D., Summers P. R. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998 Feb;178(2):203–211. doi: 10.1016/s0002-9378(98)80001-x. [DOI] [PubMed] [Google Scholar]
  16. Sobel J. D., Muller G. Ketoconazole in the prevention of experimental candidal vaginitis. Antimicrob Agents Chemother. 1984 Feb;25(2):281–282. doi: 10.1128/aac.25.2.281. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES